Gayen Shameek, Dachert Stephen, Lashari Bilal H, Gordon Matthew, Desai Parag, Criner Gerard J, Cardet Juan Carlos, Shenoy Kartik
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University Hospital, Philadelphia, PA 19140, USA.
Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL 33602, USA.
J Clin Med. 2024 Feb 1;13(3):859. doi: 10.3390/jcm13030859.
Severe asthma exacerbations, including near-fatal asthma (NFA), have high morbidity and mortality. Mechanical ventilation of patients with severe asthma is difficult due to the complex pathophysiology resulting from severe bronchospasm and dynamic hyperinflation. Life-threatening complications of traditional ventilation strategies in asthma exacerbations include the development of systemic hypotension from hyperinflation, air trapping, and pneumothoraces. Optimizing pharmacologic techniques and ventilation strategies is crucial to treat the underlying bronchospasm. Despite optimal pharmacologic management and mechanical ventilation, the mortality rate of patients with severe asthma in intensive care units is 8%, suggesting a need for advanced non-pharmacologic therapies, including extracorporeal life support (ECLS). This review focuses on the pathophysiology of acute asthma exacerbations, ventilation management including non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV), the pharmacologic management of acute asthma, and ECLS. This review also explores additional advanced non-pharmacologic techniques and monitoring tools for the safe and effective management of critically ill adult asthmatic patients.
重度哮喘急性发作,包括濒死型哮喘(NFA),具有高发病率和死亡率。由于严重支气管痉挛和动态肺过度充气导致的复杂病理生理学,重度哮喘患者的机械通气困难。哮喘急性发作时传统通气策略的危及生命的并发症包括因肺过度充气、气体潴留和气胸导致的全身性低血压。优化药物治疗技术和通气策略对于治疗潜在的支气管痉挛至关重要。尽管进行了最佳的药物治疗和机械通气,但重症监护病房中重度哮喘患者的死亡率仍为8%,这表明需要先进的非药物治疗,包括体外生命支持(ECLS)。本综述重点关注急性哮喘发作的病理生理学、通气管理,包括无创通气(NIV)和有创机械通气(IMV)、急性哮喘的药物治疗以及ECLS。本综述还探讨了用于安全有效管理重症成年哮喘患者的其他先进非药物技术和监测工具。